AngioDynamics Inc. (NASDAQ:ANGO) reached a new 52-week high on Wednesday . The company traded as high as $17.42 and last traded at $17.41, with a volume of 125,989 shares. The stock had previously closed at $16.89.

A number of equities research analysts have weighed in on ANGO shares. KeyCorp set a $18.00 target price on AngioDynamics and gave the stock a “buy” rating in a research report on Monday, September 12th. Zacks Investment Research upgraded AngioDynamics from a “sell” rating to a “hold” rating in a research report on Monday, July 25th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $15.08.

The stock’s 50-day moving average is $16.32 and its 200-day moving average is $13.84. The company’s market cap is $634.11 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/angiodynamics-inc-ango-hits-new-12-month-high-at-17-42.html

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings results on Wednesday, July 13th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.16 by $0.03. AngioDynamics had a negative net margin of 12.57% and a positive return on equity of 3.94%. The firm earned $93.40 million during the quarter, compared to analyst estimates of $88.64 million. During the same quarter in the prior year, the business posted $0.14 earnings per share. The company’s quarterly revenue was up 2.8% compared to the same quarter last year. Equities analysts forecast that AngioDynamics Inc. will post $0.63 EPS for the current fiscal year.

In other news, Director David F. Burgstahler sold 2,250,000 shares of the firm’s stock in a transaction that occurred on Friday, August 5th. The shares were sold at an average price of $14.62, for a total transaction of $32,895,000.00. Following the completion of the sale, the director now owns 23,988 shares of the company’s stock, valued at $350,704.56. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Avista Capital Partners Gp, Ll sold 2,241,000 shares of the firm’s stock in a transaction that occurred on Friday, August 5th. The stock was sold at an average price of $14.62, for a total transaction of $32,763,420.00. The disclosure for this sale can be found here. 1.88% of the stock is currently owned by corporate insiders.

Several hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. purchased a new stake in AngioDynamics during the first quarter valued at $3,552,000. Bellevue Group AG bought a new stake in AngioDynamics during the first quarter valued at approximately $1,861,000. Dimensional Fund Advisors LP boosted its stake in AngioDynamics by 4.3% in the second quarter. Dimensional Fund Advisors LP now owns 2,968,384 shares of the company’s stock valued at $42,655,000 after buying an additional 121,841 shares during the period. BlackRock Fund Advisors boosted its stake in AngioDynamics by 6.3% in the second quarter. BlackRock Fund Advisors now owns 1,796,317 shares of the company’s stock valued at $25,813,000 after buying an additional 106,151 shares during the period. Finally, Systematic Financial Management LP boosted its stake in AngioDynamics by 11.4% in the second quarter. Systematic Financial Management LP now owns 871,046 shares of the company’s stock valued at $12,516,000 after buying an additional 88,967 shares during the period. 70.01% of the stock is owned by institutional investors.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

5 Day Chart for NASDAQ:ANGO

Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.